April 2024
·
9 Reads
This page lists works of an author who doesn't have a ResearchGate profile or hasn't added the works to their profile yet. It is automatically generated from public (personal) data to further our legitimate goal of comprehensive and accurate scientific recordkeeping. If you are this author and want this page removed, please let us know.
April 2024
·
9 Reads
December 2023
·
161 Reads
Journal Of The Indonesian Medical Association
Introduction: Military pilots require good cardiorespiratory fitness due to the need to perform tasks in difficult and varied environmental conditions. Cardiorespiratory fitness is usually expressed in terms of maximal oxygen consumption (V̇O2 max). It is important to know the factors associated with V̇O2 max in order to maintain the fitness of Indonesian Air Force pilots. This study was conducted to assess the association between body fat percentage with V̇O2 max of Indonesian Air Force pilots. Methods: A cross-sectional study was conducted on active Indonesian Air Force pilots who carried out periodic medical examinations from October to November 2022 at Lakespra dr. Saryanto, Jakarta. The research subjects underwent body composition examinations using Bioelectrical Impedance Analysis (BIA), and V̇O2 max assessment was conducted using the Bruce protocol. The association between body fat percentage and V̇O2 max value was assessed by Pearson's correlation test. Results: Of the 64 subjects analysed, the average value of V̇O2 max was 44.6±6.2 ml/ kg/min and the average body fat percentage was 23.4±5.0 %. There is a significant correlation between body fat percentage and V̇O2 max. (r=-0.334; p=0.007) Conclusion: There is a significant negative correlation with moderate strength between the body fat percentage and the V̇O2 max of Indonesian Air Force pilots who carried out medical examination at Lakespra dr. Saryanto.
June 2023
·
40 Reads
·
3 Citations
Background: This study aimed to determine the real-world safety and effectiveness of remdesivir in hospitalized adult COVID-19 patients with moderate-to-critical disease in Indonesia. Methods: A multicenter, retrospective cohort study was conducted at four COVID-19 referral hospitals in Jakarta. A total of 587 patients were included, of whom 243 received remdesivir within 72 h of admission. The safety endpoints were the proportions of patients with any adverse event (AE), any grade 3 AE, and AE of each system organ class. The effectiveness endpoints were ICU admission >24 h from baseline, live discharge and mortality at day 14, live discharge and mortality at day 28, and virologic conversion. Patients who received remdesivir within 72 h of admission were considered the treatment group, and those who did not were the control group. Multivariate adjustments were performed using a modified Poisson regression. Results: The study found no significant differences in safety endpoints between the two groups. However, the effectiveness endpoints showed that remdesivir was associated with a decreased risk of ICU admission >24 h from baseline (RR 0.71, 95% CI 0.52–0.96), an increased probability of live discharge at day 14 (RR 1.37, 95% CI 1.08–1.74), and an increased probability of live discharge at day 28 (RR 1.28, 95% CI 1.05–1.57). The rate of virologic conversion was not significantly different between the two groups. Conclusion: The study concludes that remdesivir is safe and effective in the treatment of moderate-to-critical COVID-19 in a real-world setting in Indonesia.
May 2023
·
57 Reads
The Journal of Infection in Developing Countries
Introduction: As an endeavor to control SARS-CoV-2 infection, the Moderna vaccine booster was given to healthcare workers to prevent reinfection and reduce the risk of complications from COVID-19. A heterologous booster vaccine is also thought to provide better protection against the current SARS-CoV-2 variants of concern. However, research that evaluates the effectiveness of the Moderna vaccine booster and the resulting SARS-CoV-2 antibody concentration is needed. Objective: To evaluate the concentration of SARS-CoV-2 antibodies after the Moderna vaccine booster and the severity of SARS-CoV-2 infection before and after the Moderna vaccine booster. Results: A total of 93 healthcare providers who received Moderna vaccine booster were included in the study. Examination of antibody concentration 3 months after the booster showed an average concentration of 10081.65 U/mL. There was an increase in antibody concentration before the booster and 3 months after, from a median of 1.7 U/mL to 9540 U/mL. Every subject showed a statistically significant increment of antibody concentration 3 months after the booster (p < 0.01). Thirty-seven (39.8%) subjects received two doses of the Sinovac vaccine and were confirmed to have COVID-19 with the Delta variant. After the booster, 26 (28%) subjects were infected with the Omicron Variant. Among the subjects who received two doses of the Sinovac vaccine and were confirmed with COVID-19, 36 (30.1%) had mild symptoms, and 1 (1.1%) was asymptomatic. Conclusions: Heterologous Moderna vaccine booster effectively increases antibody response against SARS-CoV-2 variants and shows mild symptoms of COVID-19 infection.
June 2022
·
17 Reads
·
8 Citations
GERMS
Introduction: Coronavirus disease-2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) manifests in a broad clinical spectrum. COVID-19 survivors report various symptoms up to several months after being infected. The purpose of this study was to determine the prevalence of persistent COVID-19 syndrome in Indonesia, the factors that influence the incidence, and the quality of life. Methods: This was a cross-sectional study with an online questionnaire conducted in January 2021. Inclusion criteria were: adult Indonesian citizens who had recovered from COVID-19, and were confirmed negative by RT-PCR of nasal swabs or had undergone an isolation period for a minimum of 14 days. Data analysis was performed by the Chi-square test, followed by multivariate analysis with the backward likelihood ratio method. Results: From a total of 385 respondents, 256 (66.5%) experienced persistent COVID-19 syndrome. The most prevalent symptoms were fatigue (29.4%), cough (15.5%), and muscle pain (11.2%). Of the five aspects of quality of life, the most commonly reported aspects were pain/discomfort and anxiety/depression. The risk of persistent COVID-19 syndrome was significantly higher in subjects with older age, comorbidities, higher clinical severity, previous treatment in hospital, presence of pneumonia, and those who had required oxygen therapy. In the multivariate analysis, the most influential factor for the incidence of persistent COVID-19 syndrome was pneumonia (aOR 2.31, 95% CI 1.29-4.11, p<0.002). Conclusions: The prevalence of the persistent COVID-19 syndrome in Indonesia was high, which affects the quality of life of COVID-19 survivors. Pneumonia was the main factor that influenced the incidence of persistent COVID-19 syndrome. Further research with a larger sample size and a longer study time is recommended to control COVID-19 and its impact on the health and quality of life of COVID-19 survivors.
May 2022
·
11 Reads
February 2022
·
67 Reads
·
6 Citations
The International Journal of Tuberculosis and Lung Disease
BACKGROUND: Treating multidrug-resistant TB (MDR-TB) remains challenging. However, the determinants and timing of poor outcomes during MDR-TB treatment are still poorly understood. METHODS: We conducted a retrospective cohort study on all adult MDR-TB patients treated at Persahabatan Hospital, Jakarta, Indonesia, between January 2013 and December 2016. Risk factors for poor outcomes were analysed using Cox regression. RESULTS: Death occurred at a median time of 6 months (IQR 4–14) and loss to follow-up (LTFU) at 7 months (IQR 3–11). In multivariate analysis, advanced age (aHR 2.91, 95% CI 1.21–6.96; P = 0.017 for age >60 years), having diabetes mellitus (aHR 2.18, 95% CI 1.25–3.82; P = 0.006) and HIV co-infection (aHR 3.73, 95% CI 1.14–12.23; P = 0.030) were predictive of poor outcome in the first 7 months of treatment, whereas history of LTFU (patients who were LTFU once: aHR 2.14, 95% CI 1.33–3.47; P = 0.002; patients who were LTFU more than once: aHR 3.61, 95% CI 1.68–7.77; P = 0.001) and baseline body mass index <18.5 kg/m ² (aHR 1.98, 95% CI 1.10–3.56; P = 0.022) predicted poor outcome after 7 months of treatment. CONCLUSION: Different subsets of patients with MDR-TB are at risk of poor outcome at different times during treatment.
January 2022
·
75 Reads
Smart Medical Journal
p align="justify"> Introduksi: Coronavirus Disease 2019 (COVID-19) merupakan penyakit infeksius yang masih menjadi permasalahan serius di dunia. Meskipun presentasi klinis utama COVID-19 adalah gejala respirasi, manifestasi gastrointestinal seperti nyeri perut dan diare dapat ditemukan sebagai satu-satunya presentasi dari penyakit ini. Swab anal dapat dilakukan untuk penegakkan diagnosis COVID-19 dengan presentasi gastrointestinal. Namun perananya dalam diagnosis COVID-19 masih belum diketahui secara pasti. Laporan kasus: Laporan kasus ini membahas seorang pasien dewasa yang datang dengan keluhan gastrointestinal tanpa adanya gejala respirasi. Pasien ini kemudian terkonfirmasi COVID-19 melalui pemeriksaan polymerase chain reaction (PCR) pada sampel swab nasofaring dan swab anal. Diskusi: COVID-19 dapat ditandai dengan berbagai gejala dari organ tubuh manapun, salah satunya adalah gejala gastrointestinal. Swab anal menjadi sampel yang cukup representatif dalam membantu penegakkan diagnosis COVID-19 dengan gejala gastrointestinal. Kesimpulan : Di tengah pandemi ini, presentasi gastrointestinal tanpa gejala respirasi perlu dipertimbangkan sebagai presentasi klinis atipikal dari COVID-19. Hal ini menuntut kehati-hatian tenaga kesehatan untuk menghindari misdiagnosis COVID-19 dengan menggunakan pengambilan sampel dari organ lain seperti swab anal. </div
November 2021
·
22 Reads
·
5 Citations
Jurnal Respirologi Indonesia
Background: Cytokine storm or hyperinflammation condition in COVID-19 patients could result in fatal outcomes. Inflammation could also result in coagulation disorders. The Neutrophil-Lymphocyte Ratio (NLR) and Platelet-lymphocyte ratio (PLR) have been known as inflammation markers in several diseases. D-dimer value can be used to assess a patient's coagulation status. Further study on thromboinflammation biomarkers in COVID-19 patients is needed. Therefore, we conducted a study to assess the association between NLR, PLR, and d-dimer on the clinical outcome of confirmed COVID-19 patients at Persahabatan Central Hospital.Methods: Observational cohort retrospective analysis was conducted on 214 medical records of confirmed COVID-19 patients who meet the inclusion criteria in Persahabatan Central Hospital from March to July 2020.Results: The mean patient’s age in this study is 54.35 years, dominated by male patients (60.7%). Most of the patients had normal nutritional status (54.7%). The proportion of patients with comorbidities is 65.4%. The most common comorbid is hypertension, followed by diabetes mellitus. 76.1% of patients have severe-critically ill disease, followed by moderate (20.1%) and mild disease (3.7%) The length of hospitalization median were 12 days. Sixty patients (28%) have died during hospitalization. The median of initial value of NLR, PLR, and d-dimer is 5.75 (0.68–81.5), 243.5 (44.7–1607), and 1140 (190–141300) respectively. We found significant associations between NLR (p = 0.000), PLR (p=0.013) and d-dimer (p = 0.032) on clinical outcome. Conclusion: Initial value of NLR, PLR, and D-dimer of confirmed COVID-19 patients at Persahabatan Central Hospital were associated with clinical outcome.
March 2021
·
79 Reads
·
13 Citations
The Journal of Infection in Developing Countries
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel coronavirus that causes coronavirus diseases 2019 (COVID-19). The SARS-CoV-2 is very contagious and nobody is known to be immune to it. The post-infected lung would leave a scar known as fibrosis, a scar tissue. A study from Wuhan, China suggested the development of fibrosis, though it was too early to label these lung changes as irreversible fibrosis in a time range of 3 weeks. The occurrence of fibrosis indicates a chronic infection which greatly contributes to the hallmark symptom of COVID-19 induced ARDS such as shortness of breath and chest pain. However, many of those studies have not yet explained the condition of the patient's lung after total recovery from the COVID-19. This report demonstrates the clinical symptoms, chest CT scan, spirometry, and blood gas analysis of patient after total recovery from the COVID-19 with appearance lung fibrosis.
... 11 The first cohort study, the REMISI Study, evaluated the safety and effectiveness of antiviral drugs (Remdesivir and Favipiravir) in COVID-19 patients following Emergency Use Authorization (EUA) in Indonesia during the Delta wave (April-August 2021). 12 The second study, the MEGACRON Study, was a prospective cohort study that compared the effects of antiviral therapy on PCR conversion in hospitalized COVID-19 patients during the Omicron wave in Jakarta (January-February 2022). ...
June 2023
... Elevated neutrophil counts and an increased NLR have been identified as potential indicators of prolonged hospitalization among COVID-19 patients. 25 Neutrophilia, characterized by elevated neutrophil levels, is associated with severe COVID-19 disease and adverse outcomes. Studies, such as the one conducted by Liu et al., have reported that higher neutrophil counts are significantly correlated with disease severity and prolonged hospital stays in COVID-19 patients. ...
November 2021
Jurnal Respirologi Indonesia
... Fatigue, muscle aches, and dyspnea are the most frequent symptoms of long COVID. 2,3 The elderly population has a greater likelihood of experiencing severe disease progression, particularly if they have concurrent conditions like diabetes, hypertension, heart disease, or stroke. Furthermore, elderly individuals with comorbidities carry a higher risk of ICU admission and death. ...
June 2022
GERMS
... Dear Editor, In 2022, there were an estimated 671,000 incidents of TB among people living with HIV (PLWH) worldwide, resulting in 167,000 deaths. 1 Fortunately, the number of deaths has declined steadily over the years. 1 However, especially in patients with drug-resistant TB, HIV coinfection has repeatedly been shown to be a strong predictor of a poor treatment outcome. 2,3 Even alone, drug-resistant TB (DR-TB) is associated with poor outcomes. 4 Without appropriate treatment, among PLWH with extensively drug-resistant TB (XDR-TB), mortality rates have historically approached 100%. ...
February 2022
The International Journal of Tuberculosis and Lung Disease
... Out of seven studies, three studies reported the history of previous TB treatment. A study by Rahmawati et al, reported that in MDR-TB patients, the most common of the previous TB was TB category 1 (59,7%), category 1 and 2 (36,1%) (Rahmawati et al, 2019). ...
July 2019
Jurnal Respirologi Indonesia
... Precisely on January 10, 2020, it was identified that the infection was caused by the new coronavirus after the genetic code was discovered. According to the WHO, coronaviruses are a large family of viruses that can cause respiratory infections ranging from the common cold to more severe illnesses such as Middle East Respiratory Sindrome (MERS), and Severe Acute Respiratory Syndrome (SARS) (Handayani et al., 2020a) Further research showed that there was a close relationship with the coronavirus, which was the cause of the Severe Acute Respitatory Syndrome (SARS) that broke out in Hong Kong in 2003, so the WHO named it a novel coronavirus (nCoV19). Not long after that there began to be reports from several other provinces of China and had spread out of China, this is JOURNAL SYNTAX IDEA p-ISSN: 2723-4339 e-ISSN: 2548-1398Vol. ...
April 2020
Jurnal Respirologi Indonesia
... Meanwhile, another study indicated that the value of pulmonary diffusion capacity and spirometry examination in pilots were generally normal. However, a small number experienced a mild decrease, but there was no significant relationship between Diffusing Capacity of The Lungs for Carbon Monoxide (DLCO) parameters and age, BMI, combat flight hours, total flight hours, and sports minutes (Ningsih et al., 2020). Kim et al. (2022), BMI has a correlation with TUC because excess BMI in the presence of excess body fat can cause various diseases, including heart disease, diabetes, and hypertension, which also affect cognitive function. ...
January 2020
Jurnal Respirologi Indonesia
... Prior research demonstrated potential additive or synergistic deleterious effects of pulmonary virus infections with damage induced by preexisting lung diseases, and with ionizing irradiation-induced lung damage (21)(22)(23)(24)(25). There is emerging evidence that latestage effects of COVID-19 infection may include similar pathways (26)(27)(28)(29)(30)(31)(32)(33)(34)(35) leading to pulmonary fibrosis (34)(35)(36)(37)(38)(39)(40)(41)(42). Lung fibrosis may involve several different initiating steps (42)(43)(44)(45)(46)(47)(48)(49)(50)(51)(52)(53)(54)(55). ...
March 2021
The Journal of Infection in Developing Countries
... According to data from the Republic of Indonesia's Ministry of Health 2020, fever, coughing, lethargy, and shortness of breath are the most typical signs and symptoms of COVID-19 infection. Fever and respiratory problems were the most often reported symptoms in the Wuhan study [17]. ...
May 2020
Journal Of The Indonesian Medical Association
... On December 31, 2019, the World Health Organization (WHO) China Country Office reported a case of pneumonia of unknown etiology in Wuhan City, Hubei Province, China. On January 7, 2020, China identified pneumonia of unknown etiology as a new type of coronavirus or Covid-19 [1]. The rapid spread of Covid-19 acute respiratory syndrome is causing a worldwide pandemic. ...
January 2020